July 8, 2025 - In the latest analyst action, HC Wainwright & Co. has reiterated its "Buy" rating for Legend Biotech (LEGN, Financial). This decision aligns with the firm's previous stance, maintaining a stable outlook for the stock.
Analyst Mitchell Kapoor, representing HC Wainwright & Co., confirmed that the firm continues to hold its price target for Legend Biotech at $75.00 USD. There is no change from the prior assessment, reflecting confidence in the company's projected performance.
Legend Biotech (LEGN, Financial) remains a strong contender in the biotechnology sector, with analysts maintaining consistent positive ratings. The reiterated price target suggests a steady belief in the stock's potential value.
Investors should take note of HC Wainwright & Co.'s continued support, as Legend Biotech (LEGN, Financial) positions itself for growth opportunities in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for Legend Biotech Corp (LEGN, Financial) is $76.49 with a high estimate of $94.00 and a low estimate of $53.12. The average target implies an upside of 113.24% from the current price of $35.87. More detailed estimate data can be found on the Legend Biotech Corp (LEGN) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Legend Biotech Corp's (LEGN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Legend Biotech Corp (LEGN, Financial) in one year is $391.35, suggesting a upside of 991.02% from the current price of $35.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Legend Biotech Corp (LEGN) Summary page.
